R&D spending: $6,156,000
Percentage of revenues: 37.5%
2019 overall revenue ranking: 99
Brainsway is developing deep transcranial magnetic stimulation to treat brain disorders.
Currently, the system is FDA-cleared to treat depressive episodes in adults who have major depressive disorder and who have not had success with anti-depressant medication treatment.